Physician profile
Roma Patel
NPI 1942760533
$1,332.33
in general payments reported to CMS, 2019-2025
11 companies · $566 in 2025
The $566 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $34.09 · 2022: $16.71 · 2023: $209 · 2024: $507 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,281.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $300.87 | 2023-2025 | Wegovy, Ozempic |
| Steris Corporation | $234.67 | 2024-2025 | |
| Boston Scientific Corporation | $228.20 | 2025 | General - Biliary Devices, Apollo Esg System, Overstitch Nxt Endoscopic Suturing System |
| Janssen Biotech, INC. | $129.16 | 2024-2025 | Tremfya, Stelara |
| 3-D Matrix, INC. | $94.65 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.04 | 2023-2024 | Xifaxan, Trulance, Plenvu |
| Lilly USA, LLC | $59.66 | 2023 | |
| Abbvie INC. | $59.17 | 2022-2025 | |
| Vivus LLC | $51.21 | 2024-2025 | Qsymia |
| Phathom Pharmaceuticals, INC. | $36.42 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $17.19 | 2025 | Vowst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roma Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.